Asbestos Law Firms

Actos Bladder Cancer : Bladder tumor “seeding” may occur during the procedure. As the tumors are resected, cancer cells are released into the irrigant which fills the bladder. These cells may implant in other areas of the bladder traumatized during the procedure. It should be understood that the bladder is generally filled with urine, and tumor cells can naturally implant at other locations even without surgery. Implantation can be lessened during surgery by avoiding injury to other bladder areas and by the use of adjuvant intravesical chemotherapy. There have been numerous studies over the past decade showing a number of chemotherapy agents can be effective in decreasing initial tumor recurrence, possibly by preventing seeding. Reduction in recurrence may however be short lived.

Previously, it was common practice to obtain multiple random bladder biopsies at the time of initial tumor resection. This was recommended to rule out the possibility of hidden CIS. Understanding these biopsy sites may increase the possibilities of tumor recurrence by tumor seeding, biopsies are now often limited to areas adjacent to the tumors removed and suspicious appearing areas only. CIS can be ruled out by using cytology, or by obtaining biopsies during future cystoscopy after the tumor has already been removed. When dealing with low grade tumors, random biopsies of the bladder will rarely show cancer.

After your procedure, depending on the level of anesthesia and the extent of surgery, you will be brought either to the recovery room or back to the area where you were first prepared for your procedure. You will be released to home only when you have fully recovered from you anesthetic and are doing well. The recurrence rate for superficial bladder cancer can be as high as 60-90%. Recurrences can cause bleeding and other difficulties and are best handled sooner rather than later. In addition, depending on the initial tumor grade and stage, progression to a more serious form of bladder cancer is an ongoing concern. Surveillance cystoscopy is therefore recommended. Cystoscopy is still the best means to check for recurrent disease. It is however, an invasive procedure and should be accomplished only as often as required. For solitary, low grade, non invasive disease, follow up cystoscopy can be accomplished with the flexible cystoscope if available. If negative at three months, further cystoscopic exams can be done yearly and eventually lengthened even further. For those with multiple tumors, large tumors, high grade tumors or those who also have CIS, frequent cystoscopies, initially every three months are called for. As long as there are no recurrences, the time between cystoscopies can be lengthened. Cytology can also be utilized to reduce the number of cystoscopies. If recurrence or progression does occur, heightened scrutiny is again called for.

More information on Actos Bladder Cancer

Adverse reactions are side effects of treatment. Approximately 95% of individuals will tolerate treatments well. Adverse reactions may be mild. Common reactions include cystitis (inflammation of the bladder characterized by burning on urination), hematuria, mild fever, malaise, and nausea. These symptoms generally pass without any treatment. For bothersome symptoms, various medications may prove helpful. Your physician can prescribe medication for burning or urinary frequency. For those with persistent cystitis, antibiotics can be utilized. For individuals experiencing severe symptoms lasting more than 48 hours, isoniazid, an anti-tuberculous drug can be prescribed.

A short course of 3 days, starting the day before the next dose of BCG can be used to prevent severe side effects. Fortunately severe reactions resulting in sepsis, a life threatening condition characterized by high fever, chills and drop in blood pressure, is exceedingly rare. Sepsis would be treated in a hospital with triple anti-tuberculous drugs, steroids, and broad spectrum antibiotics. There are other serious adverse reactions which may require dose reduction or discontinuation. These are all rare and include: inflammation of the prostate, persistent hematuria, hepatitis, inflammation of the testicles and or epididymis, bladder contraction, ureteral obstruction, joint pain or inflammation of the lungs.

Recurrence of bladder cancer after the initial induction course, or relapse after complete response, would indicate failure of therapy. When two or more courses result in recurrence or when recurrence develops during the first six to twelve months after induction and maintenance therapy, patients generally are felt to have disease which is at higher risk for progression. A high percentage of patients who are complete responders remain tumor free for up to five years. However, with the passage of more time, additional patients will have late recurrences. For those with late recurrences (two to three years after therapy), most will respond to repeat BCG therapy.

Information from other sources on Actos Bladder Cancer

Invasive bladder cancer is often recognizable to the urologist by its appearance during cystoscopy. These cancers are generally large, sometimes multi-focal, and solid in appearance as compared to the fine papillary appearance of superficial bladder cancers. During the transurethral resection of the tumor, the urologist can generally tell the tumor is invading into the deeper portions of the bladder wall.

The pathologist’s report will then indicate the grade of the cancer and the depth of invasion. If the tumor invades into muscle, it is an invasive tumor. Further staging would then include a CT Scan or MRI to assess local contiguous spread, lymph node spread, or more distant spread of the cancer. A chest X ray is also routine. If there are any suspicious areas, a CT Scan of the chest is ordered. A bone scan is generally not required unless the individual has had a new onset of bony pain that is not explained by injury or arthritis.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

http://www.seedol.com

Actos Warning : Chronic urinary tract infection had been related to BC, particularly with invasive squamous cell carcinoma. , Bladder schistosomiasis has particularly been consid­ered by the international agency for research on cancer (IARC) as a definitive cause or urinary BC with an associated fivefold risk. Schistosomiasis is the second most common parasitic infection after malaria and about 600 million people are exposed to infection in Africa, Asia, South America, and Caribbean (Khurana et al. 2005).The first to report on bilharziasis association with BC was Ferguson in 1911 and later on reports of the NCI registry stated that frequency of BC in Egypt was elevated, being 27.6% of all cancers (Gouda et al. 2007).

More information on Actos Warning

Although the relationship between squamous cell carcinoma of bladder and schistosoma infection is well established, currently the trends of BC in endemic zones, as Egypt, are changing. In fact, data from the largest tertiary cancer hospital in Egypt, NCI Cairo, were analyzed to verify the incidence of squamous cell carci­noma in the area. Data from 1980 to 2005 were obtained and data from 2778cases were available for analyses. The authors demonstrated a statically significant asso­ciation between period of diagnoses and histopathological type. In this way, patients diagnosed in 2005 had a sixfold higher odds associated to transitional cell carcinoma compared to those patients diagnosed in 1980 (Felix et al. 2008). Bilharzias associa­tion dropped from 82.4% to 55.3% and there was a significant increase of transi­tional cell carcinoma from 16% to 65%, while squamous cell carcinoma was less frequent, from 76% to 28%. Intimately related to this, there was an increase in the median age of patients from 47 to 60 years. The decline in the frequency of BC is related to a decline in bilharzias egg positivity in the specimen and this suggests a better control of the endemic disease in rural population (Gouda et al. 2007).

Information from other sources on Actos Warning

Even though association between inflammation in schistosoma infection and squamous BC is well established, the role of inflammation due to other infections in the origin of BC, even transitional cell carcinoma, is less clear.Of the epidemiologic studies regarding urinary tract infection (UTIs) and BC, including transitional cell carcinoma, with one exception (Kjaer et al.1989), all the retrospective observational studies have demonstrated a positive association between BC and UTIs. Relative risk in these studies range between 1.4 and 16 for any history of urinary infection versus none, and similar associations have been found in men and women. To date no prospective study has been conducted to clearly establish the role of infection in bladder carcinogenesis.

Therefore, it could be possible that those positive associations result from detec­tion bias or differential recall between cases and controls. Prospective studies with large number of patients and controls are warranted to determine the role of inflam­mation in BC (Michaud 2007).

Our use of the term or terms Actos Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Warning visit our site often.

http://www.seedol.com

Multaq Liver Failure : Patients with ascites are at risk for SBP. This infection should be con­sidered in any patient with ascites who develops fever or abdominal pain. Sometimes, SBP will appear as a general deterioration in overall condition or worsening hepatic encephalopathy in the absence of fever. The diagnostic procedure for SBP is paracentesis. Usually, only a small volume of ascites fluid needs to be removed with a needle and syringe. The diagnosis of SBP is made if the white blood cell count in the ascites fluid is elevated. Treatment with antibiotics is essential and usually done intravenously in the hospital. Some studies have suggested that long­term oral antibiotics may be useful to prevent subsequent infections in individuals with recurrent episodes of SBP.

The first step in the treatment of hepatic encephalopathy is a low- protein diet. Proteins are high in nitrogen content. Ammonia and other nitrogen-containing compounds, which are toxic to the brain when not removed by the cirrhotic liver, are produced by the metabolism of pro­teins by bacteria in the colon. Therefore, meats, nuts, and other high­protein foods should be consumed only in very low quantities by individuals with hepatic encephalopathy. Vegetables, fruits, grains, and pastas should be substituted. This diet is in many aspects similar to the low-salt diet for ascites and edema.

The first-line drug treatment is usually lactulose, a sugar that is not absorbed from the gut. In part, it acts as a laxative to expel nitrogen- containing compounds from the colon before bacteria can metabolize them into substances toxic to an individual with a liver that cannot ade­quately clear them from the blood. Lactulose also causes the inside of the gut to be increasingly acidic, making it less favorable for nitrogen- containing toxins and ammonia to be absorbed. Another drug treat­ment for encephalopathy is neomycin, an antibiotic not absorbed from the gut, which kills bacteria in the colon that produce ammonia and other nitrogen-containing toxic compounds.

More information on Multaq Liver Failure

Administration of vitamin K can sometimes help the decreased pro­duction of clotting factors in patients with cirrhosis. In emergency bleeding situations, or prior to invasive medical procedures that may be necessary, fresh frozen plasma can be transfused intravenously. Fresh frozen plasma is the component of blood from which red and white cells have been removed; it contains clotting factors and other proteins. Platelet transfusions may also be given to patients with low platelet counts to help stop or prevent bleeding.

In some patients, the complications of cirrhosis become refractory to all medical therapies. As the liver continues to fail, hepatic encepha­lopathy worsens, ascites continue to accumulate, and other complica­tions worsen. These complications may no longer be responsive to medical interventions. Cachexia and muscle wasting cannot be halted no matter how many nutrients the patient receives. Kidney function may gradually fail and hepatorenal syndrome may develop. In these advanced cases of cirrhosis—also known as end-stage liver disease— only a liver transplant can save the patient’s life. The general goal of liver transplantation is to replace the patient’s liver just before compli­cations of cirrhosis become refractory to medical treatment. In ideal cases, this can be estimated. In many cases, as previously mentioned however, there is considerable uncertainty as to how soon the compli­cations of cirrhosis and liver failure will become life-threatening. Patients with cirrhosis and one or more of its complications should probably be evaluated at a center for liver transplantation at least two years before the doctor anticipates that the condition will deteriorate and medical treatment will no longer suffice to control the complica­tions.

Information from other sources on Multaq Liver Failure

HEPATITIS means “inflammation of the liver.” By now, it should be obvious that there are many causes of hepatitis, including drugs and alcohol. However, most people equate hepatitis with the liver disease caused by several different viruses. Hepatitis caused by a virus is more precisely called viral hepatitis. After alcohol, viral hepatitis is the leading cause of chronic liver disease in the United States. It is estimated that, at the present time, about one million Americans are chronically infected with the hepati­tis B vims and three to four million with the hepatitis C virus. World­wide, viral hepatitis surpasses alcohol as the number one cause of chronic liver disease. Approximately 350 million people, mostly in Southeast Asia and sub-Saharan Africa, are chronically infected with hepatitis B virus. The hepatitis C virus chronically infects about 170 million people worldwide. These numbers are staggering, especially since hepatitis B and hepatitis C are infectious diseases whose trans­mission can be prevented by avoiding certain behaviors and using some commonsense precautions. Hepatitis B can also be prevented by vaccination.

Because of advances in basic molecular biology and the large num­bers of affected individuals, diagnosis and treatment of viral hepatitis is currently the most active area of medicine related to diseases of the liver. The different forms of viral hepatitis are also the liver diseases most patients seem to have questions about. Our knowledge of viral hepatitis is still expanding, especially regarding hepatitis C, which was identified only about fifteen years ago. However, currently available information makes it possible to understand a good deal about the major hepatitis viruses and the diseases that each causes.

Before discussing the various types of viral hepatitis, it is important to have some understanding of what a virus is. This will hopefully pro­vide some insight as to why viral diseases are formidable problems. So sit tight and try to bear with a little basic biochemistry and cell biology. Some people define viruses as the simplest forms of life. It is really a matter of philosophical debate—and not science—to decide if viruses are “alive.” Like other life-forms, viruses reproduce and mutate (ran­domly change their genetic material). However, viruses do not have an independent metabolism and can replicate only within another organ­ism’s cells. You can decide for yourself if this constitutes life.

Our use of the term or terms Multaq Liver Failure is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Liver Failure visit our site often.

http://www.seedol.com

Multaq : A little background on the virus that causes hepatitis B is essential for understanding the disease, its symptoms, and especially its diagnosis. The existence of hepatitis B virus was discovered by accident in the 1960s. In 1965, Dr. Baruch Blumberg and collaborators discovered a protein of the hepatitis B virus in the blood of an Australian aborig­ine. This protein was called the Australia antigen. At the time of its discovery, the Australia antigen was not thought to be a viral protein. Over the next few years, however, Dr. Blumberg, his collaborators, and other groups proved that the Australia antigen was associated with hepatitis, specifically a form that was then known as serum hepatitis and was transmitted by blood. Dr. Blumberg was awarded the Nobel Prize in Physiology or Medicine in 1976 for this discovery.

In subsequent years, the hepatitis B virus was photographed under an electron microscope and was propagated in cell culture. Its genetic material was analyzed. A schematic diagram of hepatitis B virus. The hepatitis B virus is a member of the Hepad- naviridae family; other very similar viruses in this family cause liver disease in woodchucks, ground squirrels, and ducks. These animals have served as experimental models for research on hepatitis B.

The genetic material of hepatitis B virus is a circular strand of DNA. This circular DNA encodes four viral proteins, two of which are struc­tural proteins of the viral particle. It is important to be familiar with these proteins, especially the hepatitis B surface and core proteins, because detection of these proteins in the blood, or detection of antibodies against them, plays a critical role in diagnosis.

Hepatitis B core antigen (HBcAg) is a protein that forms the nude- ocapsid, or core, of the viral particle and is associated with the viral DNA. Hepatitis B core antigen is not readily detectable in the blood of infected individuals but can be seen in the liver cells. If the virus is rapidly replicating in the liver, a smaller form of the hepatitis B core antigen can be detected in the infected patient’s blood. This form is known as hepatitis Be antigen (HBeAg). Detection of HBeAg in the blood has important clinical significance in the diagnosis of more seri­ous and more highly contagious disease.

More information on Multaq

Acute infection with the hepatitis B virus can cause a wide range of initial conditions, from no symptoms to fulminant hepatic failure. In newborn babies, acute infection, usually transmitted from the mother at the time of delivery, generally does not cause clinical disease. In younger children, acute infection with hepatitis B virus also does not usually cause clinically apparent disease. In adults, most acutely infected individuals develop acute clinical hepatitis that varies in severity.

In most adult cases, acute infection with the hepatitis B virus causes moderate illness that spontaneously resolves, as in Case 1 above. Symp­toms of hepatitis typically occur within six to fifteen weeks after infec­tion. Symptoms include nausea, vomiting, fever, right upper quadrant abdominal pain, and jaundice. Blood ALT and AST activities are ele­vated roughly in proportion to the degree of acute inflammation and liver cell death. Elevations in blood bilirubin concentration and, in more severe cases, prolongation of PT may also occur. About 2 percent of acutely infected adults develop fulminant hepatic failure. This is what happened to the patient described in Case 2. Most of these individu­als either die or require emergency liver transplantation. The vast majority of acutely infected adults, as seen in Case 1, have spontaneous resolution of acute hepatitis. About 5 percent of individuals infected as adults go on to develop chronic hepatitis. B, as did the patient in Case 4.

Hepatitis B virus infection is the leading cause of chronic liver dis­ease in the world. Most chronically infected individuals are infected as infants or children. Chronic infection can cause various problems. Some chronically infected individuals are clinically classified as chronic carriers. Chronic carriers have no clinically apparent liver disease; how­ever, this may be an inaccurate term as some so-called chronic carri­ers exhibit evidence of hepatitis on liver biopsy. Other individuals chronically infected with hepatitis B virus have clinically apparent chronic hepatitis. Long-standing chronic hepatitis resuiting from hepatitis B can lead to cirrhosis. Long-standing hepatitis B infection is also a major risk factor for the development of hepatocellular carci­noma or primary liver cancer, which is the number one or two (along with lung cancer) cause of cancer death worldwide.

Information from other sources on Multaq

Chronic carriers are considered to be individuals persistently infected with the hepatitis B virus who do not have clinical evidence of hepatitis. The woman described in Case 3 is an example of a chronic carrier. Chronic carriers have detectable HBsAg in their blood but no signs or symptoms of hepatitis or liver disease. The diagnosis is often made during routine screening of pregnant women, as in Case 3, or of blood donors. Typically, blood ALT and AST activities are normal and there is no laboratory evidence of liver damage or dysfunction. The term chronic carrier derives from the fact that these individuals have laboratory evidence of hepatitis B virus infection but no clinical or lab­oratory evidence of liver disease. About 75 percent of chronic carriers will have no evidence of inflammation on liver biopsy and can truly be called carriers who do not have evidence of chronic hepatitis. About 25 percent of chronic carriers, however, are not really only carriers and will have evidence of inflammation on liver biopsy. These individuals have chronic hepatitis despite normal laboratory tests and no exhibi­tion of symptoms. Some so-called chronic carriers may even have cir­rhosis if liver biopsy is performed. Therefore, although almost universally used to describe patients chronically infected with hepati­tis B virus and no evidence of liver disease, chronic carrier may not technically be a correct description of all such patients. Furthermore, individuals who are defined as chronic carriers can sometimes develop clinically apparent hepatitis at a later time.

Chronic hepatitis that is clinically apparent, as in the patient described in Case 4, occurs in many individuals chronically infected with the hepatitis B virus. These individuals have detectable serum HBsAg. They may have symptoms of chronic hepatitis including fatigue, depression, loss of appetite, and other nonspecific complaints. Sometimes, the disease is clinically silent and the patient will not have symptoms. Blood tests will usually reveal elevated ALT and AST activ­ities. Sometimes, chronic hepatitis will be diagnosed only by liver biopsy in an individual who is diagnosed clinically as a chronic carrier. •*– Individuals with chronic hepatitis B infection, especially those with evidence of ongoing liver inflammation, are at risk of developing cir rhosis over time. Signs and symptoms of cirrhosis may not be appar­ent, and the diagnosis may be made only on liver biopsy. Case 4 describes such an example. Some patients with long-standing chronic hepatitis B may not even seek medical attention until they are suffer­ing from complications of cirrhosis

Our use of the term or terms Multaq is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq visit our site often.

http://www.seedol.com

Multaq FDA : Hepatitis B virus can be transmitted by sharing needles. Intra­venous drug users frequently share needles to inject heroin or cocaine, and blood is transmitted from one individual to the other via needle. In inner cities in the United States, intravenous drug use is a major risk factor for hepatitis B. Hepatitis B virus can also be transmitted by tat­tooing, acupuncture, ear piercing, and piercing of other body parts if unsterilized needles are used.

Sexual contact is another way to transmit the hepatitis B virus. Individuals with multiple sexual partners are at significantly increased risk for hepatitis B. Male homosexuals and female professional sex workers have much higher rates of hepatitis B virus infection than the genera! population. Patients at sexually transmitted disease clinics also have higher incidences of hepatitis B. Male prisoners are at increased risk for hepatitis B, most likely due to increased rates of unprotected homosexual activities among inmates and also because many are intra­venous drug users. In households with an infected individual, the sex­ual partner runs a higher risk of contracting hepatitis B than from other household contact. Sexual transmission of hepatitis B virus most often occurs by intercourse, either anal or vaginal, as hepatitis B virus can be isolated from seitien. The sexual transmission rate from infected women to men is probably less than that from men to women or men to men. Sexual transmission from women to men does occur, however.

Health care workers who are regularly exposed to blood are at increased risk for hepatitis B virus infection. The most likely route of infection is by accidental sticks with needles and other sharp equip­ment used on infected patients. The hepatitis B virus may also be trans­mitted by various other pieces of hospital equipment that can contain small quantities of blood, such as unsterilized endoscopes and mechan­ical ventilators. Hemodialysis is an important route of transmission. Patients with chronic kidney failure who receive hemodialysis are at significantly increased risk for hepatitis B virus infection. There have been sporadic case reports of hepatitis B virus transmission from health care workers to patients, but, fortunately, transmission by this route is rare. Most cases have been traced to persistently infected surgeons, dentists, or physicians who perform invasive procedures. Health care workers who transmit the hepatitis B virus to patients are almost always found to be HBeAg-positive upon blood testing.

More information on Multaq FDA

Antibodies of the IgG class against the hepatitis B core antigen (IgG anti-HBc) are present in the blood of almost all individuals who have been infected with, or possibly exposed to, the virus. These anti­bodies become detectable in the blood a few months after acute infec­tion, usually after the IgM class antibodies disappear. IgG anti-HBc persists in the blood after infection resolves, sometimes for the patient’s lifetime. It may be detected in someone with acute infection that is nearly resolved. IgG anti-HBc is not protective against subsequent hepatitis B virus infection.

Individuals with hepatitis B virus infection who clear the virus from their bodies develop antibodies against hepatitis B surface antigen (anti-HBs). If present, these antibodies indicate protection against rein­fection. Anti-HBs antibodies are virtually never present in chronically infected individuals who have HBsAg. They are also the type of anti­bodies induced by vaccination.

The significance of hepatitis Be antigen (HBeAg) has been dis­cussed previously in reference to states of high viral replication versus low viral replication. HBeAg is detectable in the blood of patients with high levels of viral replication. It is present in the blood of individuals with acute infection because, in acute infection, the virus replicates at a high level. Antibodies against HBeAg (IgG anti-HBe) are usually present in the blood of individuals with hepatitis B who do not have HBeAg, that is, those who have low-level viral replication.

In individuals with suspected acute hepatitis B virus infection, blood testing for HBsAg, IgM anti-HBc, and anti-HBs should be per­formed. Acute hepatitis B virus infection is usually suspected in the patient with new-onset jaundice and other symptoms including fatigue, right upper quadrant abdominal pain, fever, loss of appetite, nausea, and vomiting. A risk factor for infection may be elicited from the patient’s history, for example, intravenous drug use, an accidental nee­dle stick (in a health care worker), or exposure to an infected contact within the past several weeks or months. The presence of HBsAg in blood will indicate acute infection or the continued presence of the virus. The detection of IgM anti-HBc, in the absence of HBsAg, will suggest resolving infection. The presence of anti-HBs will indicate res­olution of the disease and that the patient is now immune to future infection. In rare cases, HBsAg and antibodies against it (anti-HBs) can be present at the same time. Such individuals can have complica­tions if these two types of antibodies react with each other in the bloodstream and deposit in the small blood vessels of various organs.

Information from other sources on Multaq FDA

Chronic hepatitis B is defined as infection with the hepatitis B virus for more than six months. Chronic hepatitis B infection should be sus­pected in individuals with known risk factors and individuals from parts of the world where the disease is endemic. Most patients from parts of the world where hepatitis B is endemic were infected as new­born babies or in childhood. A smaller percentage was infected as adults. Most chronically infected individuals in ‘Western countries acquired the disease as adults.

Individuals with chronic hepatitis B infection may have no symp­toms (chronic carriers) or have symptoms and clinical evidence of chronic hepatitis, cirrhosis, or even hepatocellular carcinoma. Some­times, the disease is suspected when elevated ALT and AST activities are detected on routine blood tests or testing for other purposes. The most important test to establish or exclude chronic hepatitis B is blood testing for HBsAg.

If HBsAg is detected in the blood, and presumably has been pres­ent for more than six months if no recent history of acute hepatitis can be ascertained, chronic hepatitis B virus infection is established. If HBsAg is not detected in the blood, the individual does not have chronic hepatitis B. It must be emphasized that, in the absence of HBsAg, the detection of IgG anti-HBc in the blood does not indicate a diagnosis of chronic hepatitis B. This is critical to realize and is a mis­take that I have seen many doctors make. HBsAg must be detected in the blood—or the individual does not have chronic hepatitis B. In indi­viduals who have clinical evidence of chronic hepatitis but do not have detectable blood HBsAg, a search for another cause of hepatitis (for example, hepatitis C, alcohol, drugs) should be initiated.

Our use of the term or terms Multaq FDA is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq FDA visit our site often.

http://www.seedol.com

Multaq Warnings : The large majority of patients with hepatitis A recover without complications. Hospitalization and supportive care may be necessary for very ill patients who are unable to eat or drink fluids. Occasionally, patients may suffer from fatigue and malaise for several months after the disease resolves. About 1 percent of individuals with hepatitis A, usually those over age fifty, develop serious liver failure, sometimes ful­minant. These patients require hospitalization and supportive care. In the United States, about one in three hundred cases of hepatitis A results in death or emergency liver transplantation.

Hepatitis A virus is spread primarily by the fecal-oral route. The virus is excreted in feces of infected people and infects susceptible individ­uals who consume contaminated water or foods. Water, shellfish, and salads are the most frequently implicated sources of transmission. Cold cuts, fruits, fruit juices, milk, and vegetables also have been implicated in various outbreaks. Hepatitis A is more common in underdeveloped parts of the world with poor sanitary conditions, and travelers to these regions are at an increased risk for infection. The time from infection with hepatitis A virus to onset of symptoms varies from ten to fifty days. Thirty days is the average. The greatest dan­ger of infecting others occurs during the middle of the incubation period and before presentation of symptoms. The patient remains potentially infectious up until a week or more after the onset of symptoms.

Although ingestion of contaminated food and water is the most common route of transmission, hepatitis A virus can be transmitted in other ways. Infected individuals can spread the virus to others who live in the same household or with whom they have sexual contact. In particular, hepatitis A virus may be spread by sexual practices in which the mouth comes in direct contact with the anal area of an infected indi­vidual. Homosexual men are at an increased risk for hepatitis A. Casual contact at work or in social settings usually does not spread the virus. Hepatitis A virus infection, however, can be spread among children and employees in child-care centers where a child or employee is infected. Residents and staff workers in institutions for developmentally disabled persons are at a particularly increased risk for being infected with hepatitis A virus. There also have been reports of transmission by shar­ing contaminated materials among intravenous drug users.

More information on Multaq Warnings

The most important issue regarding hepatitis A is prevention. There are three primary ways to prevent hepatitis A—hygiene, passive immu­nity, and vaccination. Hygienic measures to prevent hepatitis A infection include pre­venting the contamination of food and water and avoiding contact with contaminated foods. In many developing countries, widespread sewage systems have not been constructed, especially in rural areas. Water from lakes and rivers into which people defecate may be used for drink­ing, washing, or preparing foods. Living conditions are often crowded. Only overall improvement in the socioeconomic structure can remedy these problems. Visitors to such areas should avoid drinking from the local water supply and eating fresh fruits or vegetables that may have been washed with water from local rivers, lakes, or reservoirs. Locally caught shellfish also should not be consumed. If local water must be consumed, it should be boiled first.

People living in the same household as an individual with hepati­tis A, or individuals working in situations where the disease is com­mon, should follow commonsense rules. Hand washing should be strictly observed, especially when using the bathroom and before preparing or eating food. People working in child-care centers or insti­tutions for developmentally disabled individuals should wash their hands after changing diapers or sheets, before eating, or after any close contact with residents.

Passive immunization with immune globulin is recommended for short-term protection against hepatitis A and for persons who have been exposed to the hepatitis A virus. Immune globulin is a concen­tration of antibodies pooled from the blood of individuals with IgG antibodies against the hepatitis A virus. Immune globulin should be administered to individuals who will be traveling to endemic areas chat have not received vaccination far enough in advance of departure (about four weeks) for it to be effective. The U.S. Centers for Disease Control and Prevention (cdc.gov) provides recommendations for trav­elers going to various parts of the world. Immune globulin should also be given to individuals who may have been exposed to hepatitis A virus within two weeks of suspected exposure.

Information from other sources on Multaq Warnings

Hepatitis A vaccines provide long-term protection against hepati­tis A. Two shots administered in six- to twelve-month intervals are given. Vaccination is recommended for individuals who will travel to or work in areas where hepatitis A is endemic. Again, the U.S. Centers for Disease Control and Prevention provides recommendations for travelers to various parts of the world. The first dose of vaccine should be given at least four weeks before travel. This usually provides pro­tection for a short trip, but a booster is necessary six to twelve months later for long-term protection.

Children in communities with high rates of hepatitis A should also be vaccinated. These communities include Alaska Native villages, Native American reservations, and some religious communities, for example, the Kiryas Joel Hassidic community in New York. Homo­sexual men should also be vaccinated, as should people who use street drugs. Individuals with chronic liver diseases should be vaccinated as hepatitis A virus infection may be more severe in individuals with another underlying liver disease. This may be particularly true for indi­viduals with chronic hepatitis C. People with some other chronic dis­eases, such as inherited clotting factor deficiencies like hemophilia, should also be vaccinated. Hepatitis A vaccination is not recommended for all health care workers; however, those working in high-risk envi­ronments, such as institutions for the developmentally disabled, should receive the hepatitis A vaccine. Individuals who work with hepatitis A virus-infected animals or with the hepatitis A virus in a research lab­oratory should also be vaccinated.

Our use of the term or terms Multaq Warnings is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Warnings visit our site often.

http://www.seedol.com

Actos Side Effects atients sometimes describe feeling some abdominal pressure or discomfort, but not pain, during the flexible cystoscopy procedure. You will be awake, wearing a gown and lying on an examining table, with your knees draped and held apart. As noted above, your doctor will use anesthetic gel to numb the area where the flexible tube is inserted and then gently guide the cystoscope into the urethral opening (the eye of the penis in a man; the vaginal outlet of the urethra in a woman). Some men experience brief pressure and discomfort as the cystoscope passes over the area where the prostate is located. In most cases, the entire process, including preparation, will take about 15 to 20 minutes, and your doctor will be able to discuss the results of the flexible cystoscopy with you immediately.

The rigid cystoscopy is sometimes done when the tumor is in an inaccessible part of the bladder as well as when a more complicated biopsy is needed. It is performed in a hospital setting and can be either an inpatient or outpatient procedure. While the process is similar to flexible cystoscopy, you will be given general anesthesia and a more rigid tube will be used. Your doctor will give you specific instructions about how to prepare for the anesthesia (you will need to have someone drive you to and from the hospital) and what to expect during the brief recuperation after the procedure. You may be asked to remain overnight if you have other medical problems, such as severe heart disease.

During the IVP, you’ll be lying on a flat table, wearing a hospital gown, with the x-ray machine positioned above you on a movable jointed arm. The radiologist will take some basic x-rays and then will inject a contrast substance (usually iodine) through a vein, usually in your arm. The iodine is carried by the blood system to the kidneys, where it is removed (excreted into the urine). The iodine shows up when exposed in an x-ray. You might feel a sense of heat or burning from the iodine or have a metallic taste in your mouth. However, these sensations usually disappear after a few minutes. If you know that you are allergic to iodine, let the radiologist know and a different contrast material can be used.

As the iodine travels through your urinary tract system, a quick series of x-rays is snapped. Sometimes the radiologist will apply a gentle compression elastic band around your body to help the visualization process. You may be asked to turn over and might even be asked to empty your bladder. (The iodine should not cause any discoloration of your urine or any pain or burning during urination.) The x-rays taken before the iodine was injected and those taken after provide images for your doctor that give a visual picture of the ureters (the tubes between the kidneys and bladder) and the bladder’s anatomy and function.

More information on Actos Side Effects

The technologist then moves a transducer (an imaging gadget shaped somewhat like an oversized electric shaver with a flat head) over the area where the bladder is located. You probably will be asked to change positions or even to hold your breath for a few seconds during the process. The technologist watches on a screen to make sure that clear images are being recorded.

If any of the tests suggest the presence of a bladder tumor, your doctor will schedule other tests; they might include an MRI or a CT scan, and if a biopsy was not obtained during the flexible cystoscopy process, a surgical biopsy as well. These tests help your doctor determine where the tumors are, what type of cancer you have, and whether the cancer has invaded the muscle wall of the bladder. Depending on the results of those tests, your doctor may order a chest x-ray or even a bone scan to determine whether the cancer has spread to other areas of the body.

A CT scan is a painless, noninvasive test during which low intensity x-rays are repeatedly passed through the body’s soft tissue at different angles. A computer then processes the x-rays to show a detailed cross-section of the tissues and organs – in your case, of the bladder, liver, spleen, abdominal lymph nodes, and surrounding tissues. Sometimes the scanner will be focused on the chest and lungs to see whether cancer has spread there. From the CT scan, your doctor not only can confirm the presence of a tumor in the bladder, but can also measure its size and location, and determine whether it has spread to other nearby tissue.

Information from other sources on Actos Side Effects

The CT scanner can snap about 32 cross-section pictures or “slices” in approximately 10 seconds as the machine moves over your body. This means that you can easily hold your breath as the images are taken. For the CT scan, you’ll be lying on a table, dressed in a gown, and while you’ll be able to talk with the radiology technicians at all times over an intercom, you’ll be alone in the room and asked to lie still and hold your breath while the actual x-rays are being taken.

Like the IVP, a contrast medium is used to help the radiologist see your bladder and urinary tract. Sometimes it may be injected into the veins, as in IVP, or it may be swallowed or sometimes administered as an enema to distinguish bowel tissue from the bladder structure. Usually when diagnosing bladder cancer, doctors will want all three – intravenous, oral, and rectal scans – to help determine how deeply tumors may have invaded the bladder tissue and whether there is any spread to the abdominal lymph nodes or liver.

Some people find the taste of the contrast medium unpleasant, and if an enema is required, you’re likely to feel a brief, uncomfortable fullness while the scans are being taken. However, because of the speed of the process, the feeling that you need to expel the contrast medium doesn’t last long. You might also feel a brief flush or hot sensation when the contrast medium is injected. A CT scan takes anywhere from 5 to 30 minutes. Other than mild discomfort, there are few side effects.

Our use of the term or terms Actos Side Effects is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Side Effects visit our site often.

http://www.seedol.com

Multaq FDA : As with many liver diseases, the outward symptoms of ALD are vague and shared with a wide variety of disorders. Fatigue and weakness are the most common symptoms, but infertility and a decrease in sexual desire or function also may be present. Insomnia, difficulty concentrating, depression, tremors, and emotional problems are still other indicators.